Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma

Ho Shin Gwak, Gi Taek Yee, Chul Kee Park, Jin Wook Kim, Yong Kil Hong, Seok Gu Kang, Jeong Hoon Kim, Ho Jun Seol, Tae Young Jung, Jong Hee Chang, Heon Yoo, Jeong Hyun Hwang, Se Hyuk Kim, Bong Jin Park, Sun Chul Hwang, Min Su Kim, Seon Hwan Kim, Eun Young Kim, Ealmaan Kim, Hae Yu KimYoung Cho Ko, Hwan Jung Yun, Ji Hye Youn, Juyoung Kim, Byeongil Lee, Seung Hoon Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods: A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results: TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion: For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.

Original languageEnglish
Pages (from-to)489-495
Number of pages7
JournalJournal of Korean Neurosurgical Society
Volume54
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1

All Science Journal Classification (ASJC) codes

  • Surgery
  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma'. Together they form a unique fingerprint.

  • Cite this

    Gwak, H. S., Yee, G. T., Park, C. K., Kim, J. W., Hong, Y. K., Kang, S. G., Kim, J. H., Seol, H. J., Jung, T. Y., Chang, J. H., Yoo, H., Hwang, J. H., Kim, S. H., Park, B. J., Hwang, S. C., Kim, M. S., Kim, S. H., Kim, E. Y., Kim, E., ... Lee, S. H. (2013). Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. Journal of Korean Neurosurgical Society, 54(6), 489-495. https://doi.org/10.3340/jkns.2013.54.6.489